Navigation Links
Optima III Noninsulated Babcock Grasper, with ratchet

ProductsOptima III Noninsulated Babcock Grasper, with ratchet
Company GYRUS ACMI
Item Optima III Noninsulated Babcock Grasper, with ratchet
Features 
  • Full selection of tip configurations
  • Dual-action jaws
  • Lifetime warranty
  • Cleaning port
Description The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
Info GYRUS ACMI
Customer Service: (508) 804-2600
Web site: http://www.acmicorp.com

Related medicine products :

1. Optima Toric
2. Optima FW
3. Optima 38/SP
4. Optima L-XP 50 Hz, 220-240 VAC
5. Optima L-XP 60/50 Hz, 220-240 VAC
6. Optima L-90 K Ultracentrifuge 50 Hz, 220-240 VAC
7. Optima L-90 K Ultracentrifuge 60/50 Hz, 220-240 VAC
8. Optima LE-80 K Ultracentrifuges 60/50 Hz, 220-240 VAC
9. Optima LE-80 K Ultracentrifuges 50 Hz, 220-240 VAC
10. OptimaMAX Ultracentrifuges 110 VAC 60 Hz
11. OptimaMAX-E Ultracentrifuges 110 VAC 60 Hz
Offers the dual convenience of resecting tissue while simultaneously evacuating through a suction channel in the instrument....
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
The most traditional style of instrument, a classical punch shape with the parrot beak upper jaw to aid in the capture of tissue....
This family of punches offers the best of both worlds the lowest profile and the largest bite, facilitating end-on and lateral cutting the most versatile instrument available....
Medicine Products:
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... An article in Fortune on Monday, ... critical to organizations that deal with PCI (Payment Card ... data security, is worsening . Using numbers from ... major category out of the twelve measured improved, barring ... the craziness that has gone on in the retail ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
Breaking Medicine News(10 mins):Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3
... Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned ... that RLL has received approval from the U.S. ... Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) ... for the drug was submitted by Ranbaxy, from ...
... published in the Spring 2009 edition of Multiple ... Spinal Association ( www.UnitedSpinal.org ) and the North American ... importance of understanding the biological onset of Multiple Sclerosis ... greater understanding and treatment of MS in adults. The ...
... Two new Directors join the Board of the ... (Infectious Disease Research Institute) announced today that Dr. ... President (SVP) Scientific Affairs to assist the organization ... programs. Dr. Auditore-Hargreaves has a proven track record ...
... Hurricane Ike during a free public forum at Rice University ... Ed Emmett will discuss the leadership challenges they had to ... Guiding Houston through the Storm" will be held from 6 ... Rice campus, 6100 Main St. , In conjunction with ...
... Sick or injured African-American patients wait about ... before being transferred to an inpatient hospital bed ... national study published in the journal Academic ... underscore the urgency to find equitable, cost-effective solutions ...
... children and adolescents, with the active involvement of their ... the Seven Steps to Success described in the current ... published by Mary Ann Liebert, Inc. The article is ... A team of experts that includes physicians and psychologists ...
Cached Medicine News:Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:United Spinal Association Report Reveals the Importance of Studying Multiple Sclerosis in Children: Developing New Insights into MS in Adults 2Health News:IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs 2Health News:IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs 3Health News:Public forum at Rice with mayor and county judge marks 6-month Ike anniversary 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 3Health News:7 steps to successful child and adolescent weight loss 2
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5